Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies. The company was founded in 2017 and is based in New York, New York.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone917-336-9310
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees33
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Prevail Therapeutics (NASDAQ:PRVL) Frequently Asked Questions
What is Prevail Therapeutics' stock symbol?
Prevail Therapeutics trades on the NASDAQ under the ticker symbol "PRVL."
How were Prevail Therapeutics' earnings last quarter?
Prevail Therapeutics Inc. (NASDAQ:PRVL) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.58) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.24) by $0.66. View Prevail Therapeutics' Earnings History.
When is Prevail Therapeutics' next earnings date?
What price target have analysts set for PRVL?
4 Wall Street analysts have issued twelve-month price targets for Prevail Therapeutics' shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate Prevail Therapeutics' share price to reach $18.3333 in the next year. This suggests a possible upside of 68.2% from the stock's current price. View Analyst Price Targets for Prevail Therapeutics.
What is the consensus analysts' recommendation for Prevail Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prevail Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Prevail Therapeutics.
Has Prevail Therapeutics been receiving favorable news coverage?
News stories about PRVL stock have trended negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Prevail Therapeutics earned a news impact score of -2.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Prevail Therapeutics.
Who are some of Prevail Therapeutics' key competitors?
Some companies that are related to Prevail Therapeutics include Regenxbio (RGNX), Coherus Biosciences (CHRS), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Orchard Therapeutics (ORTX), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), Alector (ALEC), NanoString Technologies (NSTG), Twist Bioscience (TWST), BAVARIAN NORDIC/S (BVNRY), Adverum Biotechnologies (ADVM), Rubius Therapeutics (RUBY) and Cortexyme (CRTX).
What other stocks do shareholders of Prevail Therapeutics own?
Who are Prevail Therapeutics' key executives?
Prevail Therapeutics' management team includes the folowing people:
- Dr. Asa Abeliovich M.D., Ph.D., Founder, Pres, CEO & Director (Age 55)
- Dr. Brett Kaplan M.D., Chief Financial Officer (Age 45)
- Dr. Yong Dai, Chief Technology Officer (Age 48)
- Ms. Emily Minkow, Chief Bus. Officer (Age 36)
- Dr. Franz F. Hefti Ph.D., Chief Devel. Officer (Age 71)
When did Prevail Therapeutics IPO?
(PRVL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
When did Prevail Therapeutics' quiet period expire?
Prevail Therapeutics' quiet period expired on Tuesday, July 30th. Prevail Therapeutics had issued 7,353,000 shares in its IPO on June 20th. The total size of the offering was $125,001,000 based on an initial share price of $17.00. During Prevail Therapeutics' quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
Who are Prevail Therapeutics' major shareholders?
Prevail Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (40.65%), EcoR1 Capital LLC (7.04%), Citadel Advisors LLC (3.49%), Boxer Capital LLC (3.30%), Omega Fund Management LLC (1.97%) and Clal Insurance Enterprises Holdings Ltd (0.91%). View Institutional Ownership Trends for Prevail Therapeutics.
Which major investors are buying Prevail Therapeutics stock?
PRVL stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, EcoR1 Capital LLC, Citadel Advisors LLC, Boxer Capital LLC, Omega Fund Management LLC, Clal Insurance Enterprises Holdings Ltd, Laurion Capital Management LP and BlackRock Inc.. View Insider Buying and Selling for Prevail Therapeutics.
How do I buy shares of Prevail Therapeutics?
Shares of PRVL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Prevail Therapeutics' stock price today?
One share of PRVL stock can currently be purchased for approximately $10.90.
How big of a company is Prevail Therapeutics?
What is Prevail Therapeutics' official website?
How can I contact Prevail Therapeutics?
Prevail Therapeutics' mailing address is 430 EAST 29TH STREET SUITE 940, NEW YORK NY, 10016. The company can be reached via phone at 917-336-9310 or via email at [email protected]
MarketBeat Community Rating for Prevail Therapeutics (NASDAQ PRVL)
MarketBeat's community ratings are surveys of what our community members think about Prevail Therapeutics and other stocks. Vote "Outperform" if you believe PRVL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRVL will underperform the S&P 500 over the long term. You may vote once every thirty days.
